AtriCure (AtriCure) Cash And Cash Equivalents

: $84.3 Mil (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

AtriCure's quarterly cash and cash equivalents increased from Jun. 2023 ($67.24 Mil) to Sep. 2023 ($80.60 Mil) and increased from Sep. 2023 ($80.60 Mil) to Dec. 2023 ($84.31 Mil).

AtriCure's annual cash and cash equivalents increased from Dec. 2021 ($43.65 Mil) to Dec. 2022 ($58.10 Mil) and increased from Dec. 2022 ($58.10 Mil) to Dec. 2023 ($84.31 Mil).

AtriCure Cash And Cash Equivalents Historical Data

The historical data trend for AtriCure's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AtriCure Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

28.48

41.94

43.65

58.10

84.31

AtriCure Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															58.10	77.34	67.24	80.60	84.31

AtriCure Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

AtriCure (NAS:ATRC) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

AtriCure Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of AtriCure's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

AtriCure (AtriCure) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AtriCure Inc (NAS:ATRC) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

7555 Innovation Way, Mason, OH, USA, 45040

Website

https://www.atricure.com

AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.

Executives

Karl S. Dahlquist	officer: Chief Legal Officer	7555 INNOVATION WAY, MASON OH 45040
Karen Prange	director	1108 S RIO VISTA BLVD, FORT LAUDERDALE FL 33316
Maggie Yuen	director	ONE PENUMBRA PLACE, ALAMEDA CA 94502
Vinayak Doraiswamy	officer: Chief Scientific Officer	7555 INNOVATION WAY, MASON OH 45040
Deborah Lee Yount	officer: Chief Human Resources Officer	7555 INNOVATION WAY, MASON OH 45040
Tonya Austin	officer: Chief Human Resources Officer	7555 INNOVATION WAY, MASON OH 45040
Angela L Wirick	officer: Chief Financial Officer	7555 INNOVATION WAY, MASON OH 45040
Mark A Collar	director	382 BISHOPBRIDGE DR, CINCINNATI OH 45255
Regina E Groves	director	5751 COPLEY DRIVE, SAN DIEGO CA 92111
Douglas J Seith	officer: SVP of Sales and Marketing	7555 INNOVATION WAY, MASON OH 45040
Salvatore Privitera	officer: VP; Product Development	7555 INNOVATION WAY, MASON OH 45040
Justin J Noznesky	officer: SVP, Mktg & Business Develop	7555 INNOVATION WAY, MASON OH 45040
Deborah H Telman	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Scott William Drake	director	9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Sven Wehrwein	director